What the Research Says About Ketamine for Depression
A research-grounded look at ketamine treatment for depression: response rates, how KAP sessions work, who qualifies, and what the evidence still can't answer. Depression that hasn't budged after two or more medications leaves people asking a fair, skeptical question: is there actual evidence behind ketamine treatment for depression, or is it hype with an IV pole? This guide walks through what the research base currently supports, what ketamine-assisted psychotherapy adds on top of the medicine, and — just as importantly — the questions the science hasn't answered yet. Quick Answer Ketamine treatment for depression is studied mainly in adults whose symptoms haven't improved with standard antidepressants. Ketamine works on the brain's glutamate system by blocking NMDA receptors, a different target than the serotonin pathway used by SSRIs ( StatPearls ). One form — esketamine nasal spray — is FDA-approved for treatment-resistant depression in adults when used with an oral antidepressant ( SPRAVATO prescribing information ). IV ketamine for depression is used off-label. Results vary between individuals, and suitability is decided in a clinical consultation. TL;DR The strongest regulatory evidence sits with esketamine nasal spray, which carries an FDA-approved indication for treatment-resistant depression. See how the evidence base breaks down Ketamine's mechanism is pharmacologically different from SSRIs — it targets glutamate signaling, not serotonin reuptake. Read the mechanism in plain language Ketamine-assisted psychotherapy (KAP) adds structured preparation and integration sessions around the medicine session. Walk through the three phases Route matters: IV, nasal spray, and at-home oral differ in regulatory status, monitoring rules, and how thoroughly they've been studied. Compare the three routes side by side Candidacy is narrower than most marketing suggests, and several conditions are listed as contraindications on the FDA label. Check the candidacy criteria In This Article What Does the Research Actually Show About Ketamine for Depression? Why Does Ketamine Act on a Different Brain System Than SSRIs? How Does Ketamine-Assisted Psychotherapy Work, Step by Step? IV Infusion, Esketamine, or KAP — Which Route Fits Which Patient? Who Qualifies for Ketamine Treatment for Depression? How Long Does Relief Last, and What Does Maintenance Look Like? What Are the Limits of the Evidence Right Now? Frequently Asked Questions What Does the Research Actually Show About Ketamine for Depression? The clearest, most verifiable evidence point is regulatory: the FDA approved esketamine nasal spray, sold as SPRAVATO, for treatment-resistant depression in adults in combination with an oral antidepressant, and its label also describes an indication for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior ( SPRAVATO prescribing information ). That approval means a regulator reviewed controlled trial data and found the evidence sufficient for a specific, narrow population. Treatment-resistant depression (TRD) refers to depression that hasn't responded adequately to at least two antidepressant trials of adequate dose and duration. That definition matters because it is the population studied — not people trying a first antidepressant, and not everyday low mood. The National Institute of Mental Health's overview of depression describes the broader treatment landscape these patients have usually already worked through. IV ketamine for depression sits in a different category. Ketamine itself is an FDA-approved anesthetic, and its use for mood disorders is off-label, meaning a licensed clinician prescribes an approved drug for a purpose outside the labeled indication ( StatPearls ). Off-label doesn't mean unstudied or improper — it means the sponsor never pursued that specific labeling. Here's an honest map of where the different kinds of evidence sit: Line of evidence What it establishes What it does not settle FDA approval of esketamine nasal spray A regulator reviewed controlled data for a defined TRD population, plus administration and safety requirements Whether it outperforms IV ketamine, or how well it works long-term for any individual Peer-reviewed pharmacology (NMDA antagonism, dissociative effects, monitoring needs) How the drug acts and what clinicians must watch for How mechanism translates into durable symptom change Published randomized trials of IV ketamine in depression That the question has been studied in controlled conditions Effect size across diverse real-world patients; most trials are small and short Clinic-reported outcomes and case series How protocols are run in practice Anything generalizable — these are not controlled comparisons Long-term follow-up data Early signals about maintenance dosing Multi-year safety and durability, which remain thin Two things follow from that table. First, anyone quoting a precise success percentage should be able to name the study, the population, the timepoint, and the comparison group. Second, the brain-level rationale — covered in more depth in how ketamine works on the brain — is genuinely different from older antidepressants, which is why researchers keep returning to it. Key takeaway: The evidence is real and regulator-reviewed for esketamine in treatment-resistant depression, but it is narrower and younger than the marketing around ketamine often implies. Why Does Ketamine Act on a Different Brain System Than SSRIs? Ketamine is an NMDA receptor antagonist — it blocks a specific glutamate receptor in the brain ( StatPearls ). SSRIs act on serotonin reuptake. That's the whole reason ketamine entered depression research: it approaches the problem from an entirely separate pharmacological direction. Glutamate is the brain's main excitatory messenger, involved in learning and memory. Researchers propose that blocking NMDA receptors triggers a temporary shift in glutamate signaling, which in turn engages other receptors and growth-related pathways. The downstream steps most often described in the literature involve AMPA receptor activation and growth factors associated with synapse formation. These are proposed mechanisms under active study, not settled facts about why any one person's symptoms change. Neuroplasticity is the brain's ability to form and reshape synaptic connections between neurons. Clinicians and researchers frequently describe a post-dose "window of plasticity" in the days following a session, during which the brain may be more responsive to new learning. The exact length and reliability of that window haven't been pinned down. That proposed plasticity window is the entire intellectual argument for pairing medicine with therapy rather than delivering it alone. If the brain is temporarily more open to forming new patterns, the reasoning goes, structured psychological work during that period may be more useful than the same work done at a random time. It's a plausible and widely discussed rationale — and it's also why structured protocols schedule follow-up therapy rather than leaving patients to figure it out. For the session-level experience, see what a ketamine-assisted psychotherapy session involves step by step . Two practical notes that follow from the mechanism: Dissociation is expected, not a malfunction. Perceptual and dissociative effects are documented features of ketamine's action and are part of why monitored settings are used ( StatPearls ). Blood pressure changes are monitored. Cardiovascular effects are a known consideration, which is why vitals are checked during and after dosing. Key takeaway: Ketamine's glutamate-based mechanism is why researchers study it in people who didn't respond to serotonin-based drugs — but mechanism alone never guarantees an individual outcome. How Does Ketamine-Assisted Psychotherapy Work, Step by Step? Ketamine-assisted psychotherapy (KAP) is a structured protocol in which a trained therapist is involved before, during, or immediately after a supervised ketamine session, so the medicine and the psychological work are planned as one course of care rather than two separate services. Most KAP programs follow three phases: preparation, dosing, and integration. The clinical argument for the structure is the plasticity window described above — the idea that therapy scheduled close to dosing makes use of a period when the brain may be more receptive. Head-to-head research comparing KAP against medicine alone is still limited, so treat this as a reasoned protocol rather than a proven upgrade. Phase 1: Preparation — What Happens Before Dosing? Preparation usually takes one or two appointments and covers medical screening, expectation-setting, and informed consent. It is where candidacy is actually decided. A preparation visit commonly includes: Baseline symptom scoring — standardized scales such as the PHQ-9 for depression and GAD-7 for anxiety, so change can be tracked objectively rather than by memory. Vital signs and cardiovascular screening — blood pressure is checked because cardiovascular effects are a known consideration with ketamine. Full medication review — your clinician reviews everything you take, including sedatives and mood stabilizers, and decides whether anything should be adjusted. Never change a psychiatric medication on your own. Substance use and psychiatric history — active psychosis, mania, and untreated substance use disorders are screened for. Intention-setting and logistics — what you hope to work on, plus a confirmed ride home. Practical readiness matters more than people expect. Our guide to preparing for your first ketamine session covers what to eat, what to bring, and how to set up the day so you aren't rushing afterward. Phase 2: The Dosing Session — What Is the Therapist Doing? During dosing, the therapist's job is mostly quiet, attentive presence rather than active conversation. Talking is generally minimized while effects peak, because the psychological work is scheduled for afterward. A typical monitored medicine session involves: A private room with a reclining chair, blanket, and low lighting Eye shades and a curated music playlist, used in many protocols to keep attention inward Periodic blood pressure and vital sign checks throughout A clinician within arm's reach for the full session and the recovery period Session length depends on the route and the protocol your clinician sets. For the FDA-approved esketamine nasal spray, the label requires administration under the direct observation of a healthcare provider, with monitoring of the patient for at least two hours afterward ( SPRAVATO prescribing information ). IV protocols use a weight-based dose infused over a set period, with a recovery window before discharge. Phase 3: Integration — Why Is This the Part People Skip? Integration is the therapy session held shortly after dosing, where whatever surfaced gets turned into something usable — a changed habit, a boundary, a conversation, a plan. It is also the phase people most often drop, usually because it costs extra time and money and doesn't feel as dramatic as the medicine session. Integration refers to structured psychological work in the days following a dosing session, aimed at translating insight into concrete behavior change. The rationale is straightforward: if the post-dose period is a window of increased plasticity, then leaving it empty wastes the part of the protocol that therapy was scheduled to use. Programs typically book integration within a few days of dosing while the material is fresh. ⚠️ Skipping integration is a common shortcut, and it removes the therapeutic half of ketamine-assisted psychotherapy. If budget is tight, discuss a reduced integration schedule with your clinician rather than dropping it entirely. IV Infusion, Esketamine, or KAP — Which Route Fits Which Patient? Route selection usually comes down to three practical factors: regulatory status, insurance, and how mu